<DOC>
	<DOCNO>NCT00752648</DOCNO>
	<brief_summary>The objective : compare oral bioavailability plasma pharmacokinetics TMC435350 2 different solid formulation TMC435350 formulate powder blend capsule , single oral dose 200 mg healthy volunteer ; determine short term safety tolerability TMC435350 single oral dose 200 mg formulate capsule 2 different formulation tablet healthy volunteer</brief_summary>
	<brief_title>TMC435350-TiDP16-C106 : A Phase I Trial Compare Bioavailability Plasma Pharmacokinetics After Single Oral Dose TMC435350 2 Different Solid Formulations Relative Powder Blend Capsule</brief_title>
	<detailed_description>This Phase I , open-label , 3-way crossover trial 12 healthy adult volunteer compare oral bioavailability single 200 mg intake TMC435350 salt , formulate 2 different solid formulation ( tablet capsule ) single 200 mg intake TMC435350 salt , formulate powder blend capsule . TMC435350 protease inhibitor development treatment chronic hepatitis C virus ( HCV ) infection . During 3 session , volunteer receive 3 treatment accord classical 6-sequence , 3-period Williams design.The treatment administer : Treatment A : single dose 200 mg TMC435350 salt , formulate powder blend fill capsule . Treatment B : single dose 200 mg TMC435350 salt , formulate tablet . Treatment C : single dose 200 mg. MC435350 salt , formulate bead fill capsule . All medication intakes oral fed condition . There washout period least 7 day medication intake subsequent treatment session . Full pharmacokinetic profile TMC435350 determine 72 hour administration session . Safety tolerability monitor continuously throughout trial . Treatments A , B C : TMC435350 200mg Day 1 session.Intakes oral fed condition .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Nonsmoking least 3 month prior selection Normal weight define body mass index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity Able comply protocol requirement Normal 12lead electrocardiogram ( ECG ) ( triplicate ) screen include : Normal sinus rhythm ( heart rate [ HR ] 40 100 bpm ) , QTc interval = 450 m , QRS interval &lt; 120 m , PR interval = 220 m Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , vital sign , result blood biochemistry , hematology test urinalysis carry screening . Past history heart arrhythmia ( extrasystolic , tachycardia rest ) baseline prolongation QTc interval &gt; 450 m , history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT syndrome ) Female , except postmenopausal since 2 year , posthysterectomy , posttubal ligation ( without reversal operation ) Hepatitis A , B , C infection , human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection screen A positive urine drug test screening . Urine test check current use amphetamine , benzodiazepine , cocaine , cannabinoids , opioids Currently active underlie gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease Any history significant skin disease , limited , rash eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria History drug allergy , limited , sulfonamides penicillin , drug allergy witness previous trial experimental drug Participation investigational drug trial within 60 day prior first intake trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC435350-TiDP16-C106</keyword>
	<keyword>TMC435350-C106</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>